Sep 15, 2026 07:01AM
Sep 15, 2026 07:00AM
Jun 23, 2026 11:11AM
Jun 22, 2026 08:30AM
May 8, 2026 07:00AM
Apr 17, 2026 04:50PM
Apr 17, 2026 04:49PM Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Mar 9, 2026 07:00AM
Jan 20, 2026 07:01AM
Jan 20, 2026 07:00AM
Nov 5, 2025 07:00AM
May 23, 2025 04:01PM
May 9, 2025 07:00AM
Mar 27, 2025 07:00AM Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Aug 12, 2024 04:03PM
Aug 12, 2024 04:01PM
Mar 23, 2023 10:19AM
Dec 3, 2019 09:16AM
Dec 2, 2019 06:29PM
Nov 7, 2019 04:01PM
Oct 7, 2019 07:20AM Audentes Therapeutics (BOLD) Announces Positive AT132 Trial Data
Oct 5, 2019 07:01AM
Sep 30, 2019 08:00AM
Aug 6, 2019 04:53PM
Aug 6, 2019 04:01PM
May 7, 2019 04:01PM
May 1, 2019 02:16PM
May 1, 2019 02:15PM Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Th
Apr 15, 2019 04:01PM
Mar 29, 2019 08:55AM
Mar 27, 2019 09:00AM
Feb 27, 2019 04:01PM
Feb 25, 2019 09:25AM
Feb 24, 2019 09:23PM
Jan 31, 2019 08:00AM Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation
Jan 7, 2019 08:00AM
Nov 6, 2018 04:01PM
Oct 5, 2018 08:03AM
Oct 5, 2018 08:01AM
Oct 5, 2018 08:00AM
Sep 24, 2018 08:05AM
Sep 24, 2018 08:00AM Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Socie
Aug 22, 2018 06:34AM
Aug 21, 2018 08:01AM
Aug 21, 2018 08:00AM
Aug 7, 2018 06:23AM
Aug 7, 2018 06:00AM
Jul 31, 2018 08:00AM
Jun 5, 2018 08:00AM Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
May 16, 2018 11:30AM

334,247 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All